Digestive Disease Week
Digestive Disease Week
Disclosures: Webster reports consulting or advising for Bonti, BDSI, Charleston Labs, Daiichi Sankyo, Ensyse Biosciences, Elsyium Therapeutics, Insys Therapeutics, Mallinckrodt Pharmaceuticals, Merck, Neurana, Pain Therapeutics, Pernix, Pfizer, Salix, Shionogi, Teva, and Trevena.
May 11, 2020
1 min watch
Save

Relistor reduces mortality in patients with opioid-induced constipation

Disclosures: Webster reports consulting or advising for Bonti, BDSI, Charleston Labs, Daiichi Sankyo, Ensyse Biosciences, Elsyium Therapeutics, Insys Therapeutics, Mallinckrodt Pharmaceuticals, Merck, Neurana, Pain Therapeutics, Pernix, Pfizer, Salix, Shionogi, Teva, and Trevena.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

In this exclusive video, Lynn R. Webster, MD, from PRA Health Sciences in Salt Lake City, discusses his study from Digestive Disease Week that explored the impact of Relistor, a mu-opioid receptor agonist, on all-cause mortality in patients with opioid-induced constipation.

In a retrospective analysis of 11 phase 2 and 3 randomized controlled trials, researchers found that the drug (methylnaltrexone, Salix) did reduce mortality and observed significant reductions in mortality among patients with cancer.

Reference:

Webster LR, et al. Abstract 8. Presented at: Digestive Disease Week; May 2-5, 2020; Chicago (meeting canceled).

Disclosures: Webster reports consulting or advising for Bonti, BDSI, Charleston Labs, Daiichi Sankyo, Ensyse Biosciences, Elsyium Therapeutics, Insys Therapeutics, Mallinckrodt Pharmaceuticals, Merck, Neurana, Pain Therapeutics, Pernix, Pfizer, Salix, Shionogi, Teva, and Trevena.